| ●Editorial | Fukushima M | 272-4 | Full text | |
| ●5th World Centenarian Initiative International Symposium on Stroke－Innovation for longer healthy life－ Representative organizer：Matsumoto M Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation |
275-368 | Abstract | ||
| Opening remarks | Matsumoto M | 278-9 | ||
| Current status of the recurrence of non-cardiogenic strokes and the future prevention of stroke in Japan | Suzuki N | 280-5 | ||
| State of stroke in Japan | Miura K | 286-9 | ||
| Risk factors and biomarkers for stroke prevention | Kitagawa K | 290-5 | ||
| Stroke risk factors and prevention | Kamouchi M | 296-302 | ||
| Stroke registry in outcome and translational research | Jeng JS | 303-8 | ||
| Transient ischemic attack (TIA) revisited: Clinical significance and management | Lee YS | 309-12 | ||
| Translational stroke research: A personal perspective | Fisher M | 313-7 | ||
| Advances and future aspects of endovascular treatment of acute stroke | Yamagami H | 318-22 | ||
| Intracerebral hemorrhage and deep microbleeds associated with cnm-positive
Streptococcus mutans; A clue to developing a new preventive strategy | Ihara M | 323-8 | ||
| Acute treatment in stroke | Kimura K | 329-33 | ||
| Magnetic resonance in acute stroke | Igarashi H | 334-8 | ||
| Neuroprotection of neuroserpin in cerebrovascular diseases: From bench to bed | Wang L | 339-42 | ||
| Intravenous transplantation of autologous mesenchymal stem cells derived from bone marrow into stroke patients | Honmou O | 343-6 | ||
| Intra-arterial stem cell therapy in stroke patients | Banerjee S | 347-51 | ||
| Cybernic functional regeneration using Hybrid Assistive Limb (HAL) for the patients with neuromuscular and cerebrovascular diseases | Nakajima T | 352-7 | ||
| Restoration of post-stroke upper limb paralysis with BMI neurorehabilitation: From basic neuroscience to clinical application | Liu M | 358-62 | ||
| Closing remarks | Nagai Y | 363-4 | ||
| Fukushima M | 365-8 | |||
| ●The past, present and future of bioethics and research ethics (Part III) | ||||
| A Letter to Scientists ─ Deep Concerns about Dual-Use Research | Fukushima M | 369-81 | Abstract | |
| Dark Tourism: Opening a new horizon in Bioethics | Kimura R | 383-93 | Abstract | |
| Dark tourism: Is it a challenge to the dignity of humanity or a journey of requiescat? | Saio T | 395-402 | Full text | |
| Dark Tourism and the “Recovery of Humans”: Learning from the disaster victims and remembering the nuclear power plant accident together | Shimazono S | 403-11 | Abstract | |
| Dark tourism can be the fortune teller of disaster medicine | Tomioka J | 413-8 | Abstract | |
| A “dark tour” from Hiroshima, Nagasaki and Chernobyl toward Fukushima and South Africa | Kurihara C | 419-29 | Abstract | |
| Federal Policy for the Protection of Human Subjects (Common Rule), revised: Revision of Code of Federal Regulations, Title 45, Part 46, Subpart A (Basic HHS Policy for Protection of Human Research Subjects) | Sato H，Tomio J | 431-4 | Abstract | |
| Code of Federal Regulations, Title 45 (Public Welfare, Department of Health and Human Services), Part 46 (Protection of Human Subjects), Subpart A. Basic HHS Policy for Protection of Human Research Subjects | （Trans. by Tomio J，Sato H） | 435-53 | ||
| Regulations for clinical trial and human subject protection in the United States | Kurihara C | 455-80 | Full text | |
| On the ICMJE clinical trial data sharing statement: Its background and summary of its issue | Kurihara C，Saio T | 481-92 | Full text | |
| Data sharing statements for clinical trials: A requirement of the International Committee of Medical Journal Editors | Taichman DB，Sahni P， Pinborg A，et al. （Trans. by Saio T，Kurihara C） | 493-6 | Full text | |
| ●Instructions for authors［Japanese］ & ［English］ | 497-505 | Full text | ||
| ●Editor's note | Uchida E | 507 | Full text | |